Petra Arlert
Leo Pharma (Denmark)(DK)
Publications by Year
Research Areas
Dermatology and Skin Diseases, Asthma and respiratory diseases, IL-33, ST2, and ILC Pathways, Food Allergy and Anaphylaxis Research, Urticaria and Related Conditions
Most-Cited Works
- → Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis(2023)125 cited
- → Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trial(2022)47 cited
- → Targeting IL‐13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years(2024)46 cited
- → 53111 Individual patient responses to IL-22RA1 inhibition in a Phase 2a monotherapy trial for moderate-to-severe atopic dermatitis(2024)4 cited
- → 40900 Tralokinumab modulates the transcriptomic profile of lesional and non-lesional skin in adolescents with moderate-to-severe atopic dermatitis assessed by tape-stripping(2023)2 cited
- → Targeting IL-22RA1 with temtokibart: A novel approach in atopic dermatitis: Phase 2a monotherapy study results(2025)2 cited
- → Neutralizing Interleukin-13 with Tralokinumab Reduces Abundance of S. aureus in Adolescents with Atopic Dermatitis(2024)1 cited
- → 43946 Neutralization of IL-13 by tralokinumab improves atopic dermatitis endotypes characterized by S. aureus colonization(2023)1 cited
- → The impact of tralokinumab on quality of life and school in patients aged 12-17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial(2023)1 cited
- → Le tralokinumab module le profil transcriptomique de la peau (lésionnelle ou non) chez les adolescents atteints de dermatite atopique modérée à sévère(2023)